FIG. 1



Time Spent Immobile (Min:Sec)
0:05:24
0:04:19
0:03:14
0:02:10
0:01:05
0:00:00
27%
38%
*
VEH
PZP 5
PZP 25
PZP 50

FIG. 2



Time Spent Immobile (Min:Sec)
0:05:24
0:04:19
0:03:14
0:02:10
0:01:05
0:00:00
*
**
33%
51%
VEH
TZP 5
TZP 25
TZP 50

FIG. 3



Time Spent Immobile (Min:Sec)
0:05:24
0:04:19
0:03:14
0:02:10
0:01:05
0:00:00
*
*
**
45%
37%
52%
VEH
TZP 60
TZP 80
TZP 100

FIG. 4



Time Spent Immobile (Min:Sec)
0:05:24
0:04:19
0:03:14
0:02:10
0:01:05
0:00:00
24%
30%
43%
**
VEH
SRT 1.0
TZP 5.0
SRT + TZP

FIG. 5



Time Spent Immobile (Min:Sec)
0:05:24
0:04:19
0:03:14
0:02:10
0:01:05
0:00:00
10%
21%
**
aa
b
75%
VEH
VEN 10
TZP 5
VEN+TZP

FIG. 6



Time Spent Immobile (Min:Sec)
0:05:24
0:04:19
0:03:14
0:02:10
0:01:05
0:00:00
34%
54%
**
VEH
FLX 4.0
TZP 10.0
FLX+TZP

FIG. 1



Effect of Pirenzepine (PZP) on Immobility Times of CD-1 Mice Subjected to the Tail Suspension Test
Time Spent Immobile (Min:Sec)
0:05:24
0:04:19
0:03:14
0:02:10
0:01:05
0:00:00
60 min Pretreatment
VEH
PZP 5
PZP 25
PZP 50
*
27%
38%
Male, CD-1; n=10
Drugs: mg/kg, ip (as freebase)
VEH: 10% DMSO
* p<0.05 vs. VEH

FIG. 2



Effect of Telenzepine (TZP) on Immobility Times of
CD-1 Mice Subjected to the Tail Suspension Test
60 min
Pretreatment
Time Spent Immobile (Min:Sec)
0:05:24
0:04:19
0:03:14
0:02:10
0:01:05
0:00:00
*
**
33%
51%
VEH
TZP 5
TZP 25
TZP 50
Male, CD-1; n=10
Drugs: mg/kg, ip
(as freebase)
VEH: 10%DMSO
* p<0.05 ** <0.001

FIG. 3



Effect of Oral Telenzepine (TZP) on Immobility Times of CD-1 Mice Subjected to the Tail Suspension Test
Time Spent Immobile (Min:Sec)
0:05:24
0:04:19
0:03:14
0:02:10
0:01:05
0:00:00
90 min Pretreatment
VEH
TZP 60
TZP 80
TZP 100
*
*
**
45%
37%
52%
Male, CD-1; n=10
Drugs: mg/kg, po (as freebase)
VEH: Saline
* p<0.05, ** <0.01 vs VEH

FIG. 4



Effect of Sertaline (SRT), Telenzepine (TZP) or SRT + TZP on Immobility Times of CD-1 Mice Subjected to the Tail Suspension Test
60 min Pretreatment
Time Spent Immobile (Min:Sec)
0:05:24
0:04:19
0:03:14
0:02:10
0:01:05
0:00:00
24%
30%
43%
**
VEH
SRT 1.0
TZP 5.0
SRT + TZP
Male, CD-1; n=10
Drugs: mg/kg, ip
(as freebase)
VEH: 10% DMSO
* p<0.05 ** <0.01
vs VEH

FIG. 5




Effect of Telenzepine (TZP), Venlafaxine (VEN) or
TZP + VEN on Immobility Times of CD-1 Mice
Subjected to the Tail Suspension Test
Time Spent Immobile (Min:Sec)
0:05:24
0:04:19
0:03:14
0:02:10
0:01:05
0:00:00
10%
21%
75%
**
aa
b
60 min
Pretreatment
VEH
VEN 10
TZP 5
VEN+TZP
Male, CD-1; n=10
Drugs: mg/kg, ip
(as freebase)
VEH: 10% DMSO
* p<0.05 ** <0.01
vs VEH
a p<0.05 aa <0.01
vs VEN
b p<0.05 vs TZP

FIG. 6


Effect of Fluoxetine (FLX), Telenzepine (TZP) or
FLX + TZP on Immobility Times of CD-1 Mice
Subjected to the Tail Suspension Test
Time Spent Immobile (Min:Sec)
0:05:24
0:04:19
0:03:14
0:02:10
0:01:05
0:00:00
60 min
Pretreatment
VEH
FLX 4.0
TZP 10.0
FLX+TZP
**
34%
54%
Male, CD-1; n=9-10
Drugs: mg/kg, ip
(as freebase)
VEH: 10%DMSO
**. p<0.01 vs VEH